CSRXP COMMENDS PRESIDENT BIDEN FOR HOLDING BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE AND EGREGIOUS PRICING ON BRAND NAME INHALERS

President Says ‘Drug Companies Are Charging Exorbitant Prices’ in Press Conference Highlighting Big Pharma’s Anti-Competitive Practices and Price Hikes on Inhalers

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Wednesday following a press conference with President Joe Biden and U.S. Senator Bernie Sanders (I-VT) highlighting Big Pharma’s price hikes and patent abuse on brand name inhalers.

“CSRxP commends President Biden and the Administration for holding Big Pharma accountable for decades of patent abuse and price hikes on brand name inhalers,” said CSRxP executive director Lauren Aronson. “The Administration and lawmakers must continue to hold Big Pharma accountable for anti-competitive tactics designed to game the system, block competition from more affordable alternatives and keep prices high.”

Read more about how Big Pharma has gamed the patent system to boost profits and block competition on inhaler products HERE.

Read more about the cost of Big Pharma’s anti-competitive practices on brand name inhaler products HERE.

Read more about how the Federal Trade Commission (FTC) has cracked down on Big Pharma’s abuse of the patent system around inhalers HERE.

Read more on market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.